INS and Alzheimer disease: It could be speculated that in AD patients this regulation is lost, possibly because less ERp57 is secreted or the oxidative environment is not favorable, because of the aging process (Ghosh & Brewer, 2014) and therefore the Aβ, released outside the cell, is no longer digested by enzymes such as neprilysin (Campos et al., 2020) and Insulin Degrading Enzyme (Bulloj et al., 2010), triggering a fibrillation process that will eventually lead to the formation of amyloid aggregates (Erickson et al., 2005; Zhao et al., 2012).